Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Following the publication of the American Journal of Respiratory and Critical Care Medicine (AJRCCM) paper “Transcriptomic Signatures in Sepsis and a Differential Response to Steroids: From the VANISH Randomized Trial  PubMed: 30365341

We have demonstrated that sepsis response signatures (SRS)/sepsis endotypes are associated with different responses to treatment. Genome-wide gene expression profiling was performed and SRS endotype was determined using a previously established model with seven discriminant genes. We concluded that transcriptomic profile at onset of septic shock was associated with response to corticosteroids. Those with the immuno-competent SRS2 endotype had significantly higher mortality when given corticosteroids compared to placebo.